Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2024-10-04 00:00:00 ET · period of report 2024-10-03 · accession 0000950170-24-112912 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-04 | 2024-10-03 | KLRS | Brainard Diana | CEO, Dir | S - Sale | $0.81 | -1,493 | 752.4K | -0.2% | -$1,209 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-03 | S | D | 1,493 | $0.81 | 752,430 | D | — | — |